Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV‐1 infected patients failing HAART
暂无分享,去创建一个
A. Lazzarin | G. Angarano | M. Marangi | A. Saracino | N. Gianotti | A. Galli | G. Punzi | L. Monno | Donatella C. Cibelli | Donatella C. Cibelli
[1] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[2] S. Luchters,et al. Feasibility of Detecting Human Immunodeficiency Virus Type 1 Drug Resistance in DNA Extracted from Whole Blood or Dried Blood Spots , 2007, Journal of Clinical Microbiology.
[3] D. Richman,et al. Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[4] M. Zazzi,et al. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] A. Geretti,et al. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.
[6] M. Zazzi,et al. Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients , 2007, Journal of Clinical Microbiology.
[7] C. Scagnolari,et al. Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals , 2007, Journal of acquired immune deficiency syndromes.
[8] M. Re,et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[9] N. Saksena,et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. , 2007, Current HIV research.
[10] Paul Sandstrom,et al. HIV-1 drug resistance surveillance using dried whole blood spots , 2007, Antiviral therapy.
[11] W. Heneine,et al. Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance Testing , 2006, Journal of Clinical Microbiology.
[12] A. Lazzarin,et al. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] G. Angarano,et al. HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic , 2005, Journal of medical virology.
[14] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[15] N. Saksena,et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] P. Narciso,et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients , 2005, AIDS.
[17] JD Lundgren,et al. Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.
[18] S. Oka,et al. Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year , 2003, Journal of acquired immune deficiency syndromes.
[19] J. R. Fiore,et al. Mutational patterns of paired blood and rectal biopsies in HIV‐infected patients on HAART , 2003, Journal of medical virology.
[20] G. d’Ettorre,et al. Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing , 2003, Journal of Clinical Microbiology.
[21] N. Saksena,et al. Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. , 2003, Virology.
[22] P. Keiser,et al. Role of Sequencing in Therapy Selection , 2002, Journal of acquired immune deficiency syndromes.
[23] F. Baldanti,et al. Analysis of HIV drug‐resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment‐naive and HAART patients , 2001, Journal of medical virology.
[24] M. Zazzi,et al. Divergent Distribution of HIV-1 Drug-Resistant Variants on and off Antiretroviral Therapy , 2001, Antiviral therapy.
[25] N. Saksena,et al. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART , 2000, AIDS.
[26] C. Sabin,et al. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. , 2000, AIDS research and human retroviruses.
[27] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[28] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[29] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[30] C. Loveday,et al. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. , 1995, AIDS research and human retroviruses.